A phase 1 trial to evaluate the safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of VIS171 in participants with autoimmune disease(s)

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518976-30-00

Acronym

VIS171-103

Enrollment

Registered

2025-05-15

Start date

2025-07-02

Completion date

Unknown

Last updated

2026-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alopecia Areata, Immune-mediated focal segmental glomerulosclerosis, Systemic lupus erythematosus

None listed

Sex/Gender

All

Age

18 Years to No maximum

Bulgaria, Poland, Romania, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026